Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
Top Page
Niagen Bioscience
(NASDAQ:NAGE)
74Outperform
Positive Factors
Earnings Performance
ChromaDex reported impressive earnings outperformance with multiple revenue accelerants.
Revenue Growth
Niagen Plus products are now available at over 475 leading wellness clinics in the U.S., indicating a massive expansion.
Negative Factors
Clinical Trials
Key clinical study in Parkinson's disease remains slated to potentially yield top-line results in 1H25, which could significantly impact the company's prospects.
Regulatory Approval
If the NO-PARK results prove positive, ChromaDex may explore the possibility of obtaining regulatory approval for a pharmaceutical-grade formulation of NR to treat Parkinson's disease.
Niagen Bioscience (NAGE) vs. S&P 500 (SPY)
Market Cap
$678.76M
Dividend YieldN/A
Average Volume (3M)708.63K
Price to Earnings (P/E)82.9
Beta (1Y)0.80
Revenue Growth19.18%
EPS GrowthN/A
CountryUS
Employees104
SectorHealthcare
Sector Strength53
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding77,750,450
10 Day Avg. Volume810,135
30 Day Avg. Volume708,632
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.35
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.03Price Target Upside6.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Niagen Bioscience Business Overview & Revenue Model
Company DescriptionChromaDex (CDXC) is a global bioscience company dedicated to improving human health by providing innovative solutions based on scientific research. The company operates primarily in the dietary supplement sector, focusing on its flagship ingredient, Niagen, a proprietary form of nicotinamide riboside (NR), which is a precursor to NAD+ - a molecule essential for cellular energy production and repair. ChromaDex's core product offering includes Tru Niagen, a dietary supplement designed to promote healthy aging by boosting NAD+ levels in the body.
How the Company Makes MoneyChromaDex makes money through the sale of its proprietary ingredient, Niagen, and its branded dietary supplement product, Tru Niagen. The company generates revenue primarily via direct-to-consumer sales through its e-commerce platform as well as through retail partnerships with major retailers and distributors. Additionally, ChromaDex licenses its ingredient technology to third parties, which further contributes to its revenue streams. The company also invests in research and development to support product efficacy claims, enhance brand credibility, and expand its market reach through scientific validation and partnerships with research institutions.
Niagen Bioscience Financial Statement Overview
Summary
Chromadex demonstrates significant financial improvement with a shift to profitability and enhanced cash flow generation. The balance sheet is strong with low leverage, but declining revenue trends pose a risk to long-term growth. Addressing revenue growth challenges will be key.Income Statement
Chromadex shows a substantial recovery in net income from a loss of $4.94M in 2023 to a profit of $8.55M in 2024, indicating strong profitability improvements. However, revenue decreased from $83.57M in 2023 to $61.59M in 2024, resulting in a negative revenue growth rate, which is a concern. The company achieved a positive EBIT margin, shifting from a negative margin in the previous year, reflecting improved operational efficiency.65
Positive
Balance Sheet
The company has a strong equity position with a debt-to-equity ratio of 0.06, indicating low leverage. The equity ratio increased to 67.5% in 2024, up from 51.8% in 2023, highlighting a solid capital structure. Return on equity improved significantly with positive net income, reflecting enhanced shareholder value. The balance sheet is robust, but a reduction in total revenue could impact future stability.72
Positive
Cash Flow
Chromadex's free cash flow increased significantly from $6.97M in 2023 to $11.95M in 2024, showcasing strong cash generation capabilities. The operating cash flow to net income ratio is healthy, indicating efficient conversion of income into cash. Despite a decrease in investing cash flow, the strong free cash flow growth signals good financial health.78
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 99.60M | 83.57M | 72.05M | 67.45M | 59.26M | Gross Profit |
| 61.59M | 50.78M | 42.80M | 41.49M | 35.27M | EBIT |
| 7.73M | -5.60M | -18.63M | -27.07M | -19.85M | EBITDA |
| 9.21M | -3.89M | -16.74M | -25.45M | -18.34M | Net Income Common Stockholders |
| 8.55M | -4.94M | -16.54M | -27.13M | -19.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 44.51M | 27.17M | 20.29M | 28.02M | 16.50M | Total Assets |
| 68.28M | 54.96M | 54.06M | 57.84M | 38.36M | Total Debt |
| 2.65M | 3.28M | 4.26M | 4.70M | 1.64M | Net Debt |
| -41.86M | -23.90M | -16.03M | -23.32M | -14.86M | Total Liabilities |
| 22.18M | 26.51M | 25.39M | 26.11M | 21.93M | Stockholders Equity |
| 46.09M | 28.46M | 28.67M | 31.73M | 16.42M |
| Cash Flow | Free Cash Flow | |||
| 11.95M | 6.97M | -15.43M | -24.57M | -10.74M | Operating Cash Flow |
| 12.11M | 7.12M | -15.10M | -24.16M | -10.60M | Investing Cash Flow |
| -143.00K | -143.00K | -334.00K | -409.00K | -165.00K | Financing Cash Flow |
| 5.37M | -90.00K | 7.65M | 36.09M | 8.65M |
Niagen Bioscience Technical Analysis
Positive
8.45
Price Trends
7.09
Positive
6.38
Positive
5.36
Positive
Market Momentum
0.46
Negative
65.92
Neutral
86.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Positive. The current price of 8.45 is above the 20-day moving average (MA) of 7.16, above the 50-day MA of 7.09, and above the 200-day MA of 5.36, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 65.92 is Neutral, neither overbought nor oversold. The STOCH value of 86.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAGE.
Niagen Bioscience Risk Analysis
Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Niagen Bioscience Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $678.76M | 82.91 | 22.94% | ― | 19.18% | ― | |
55 Neutral | $512.10M | ― | -37.13% | ― | -38.14% | 29.69% | |
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
50 Neutral | $460.27M | ― | -1.44% | ― | 1.98% | 63.69% | |
47 Neutral | $518.20M | ― | -39.04% | ― | -10.30% | -14.44% | |
39 Underperform | $479.91M | ― | ― | -25.10% | -7.06% | ||
33 Underperform | $385.57M | ― | -99.17% | ― | ― | 19.94% |
* Healthcare Sector Average
Performance Comparison
NAGE
Niagen Bioscience
8.45
4.62
120.63%
SVA
Sinovac Biotech
6.47
0.00
0.00%
BCYC
Bicycle Therapeutics
7.78
-15.84
-67.06%
OPT
Opthea Limited Sponsored ADR
3.20
-0.09
-2.74%
MRVI
Maravai Lifesciences Holdings
2.12
-6.75
-76.10%
SANA
Sana Biotechnology
1.70
-7.79
-82.09%
Niagen Bioscience Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q4-2024)
| % Change Since: 0.00%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong financial performance with record revenues, increased cash flow, and improved operational efficiency. However, the company faces challenges in the supply chain and regulatory landscape, necessitating vigilance against market competitors' misleading practices. Overall, the positive financial results and strategic initiatives suggest a promising outlook despite these challenges.Q4-2024 Updates
Positive Updates
Record-Breaking Revenue and Growth
ChromaDex delivered record revenues of $29.1 million for Q4 2024, a 37% increase year-over-year, and net income of $7.2 million. Full year net revenues were $99.6 million, a 19% growth YOY.
Strong Cash Flow and Financial Position
Generated $12.1 million in positive cash flow from operations in 2024, ended the year with $44.7 million in cash and no debt.
E-commerce and Ingredient Business Growth
E-commerce channel net sales were $17.3 million, a 30% increase YOY. Food grade and pharmaceutical-grade Niagen ingredient business had net sales of $5.3 million, a 96% increase YOY.
Improved Operational Efficiency
Gross margins improved by 150 basis points to 62.5% in Q4 2024, reflecting operational efficiency and a strategic business mix.
Reduction in Expenses
Selling and marketing expenses as a percentage of net sales improved by 90 basis points, and general and administrative expenses decreased by $6.6 million YOY.
Strategic Initiatives and Name Change
ChromaDex plans to announce a company name change to better represent its strategic direction and growth.
Negative Updates
Supply Chain Challenges for Niagen IV
Issues in the pharmaceutical-grade supply chain delayed the availability of Niagen IV by 2 to 3 months, affecting sales.
Regulatory and Market Challenges
Faced challenges with misleading and dangerous practices by competitors in the NAD market, including patent infringements and false claims.
FDA and FTC Regulatory Actions Needed
Company expressed the need for more action from the FDA and FTC to prevent consumer deception in the NAD market.
Company Guidance
During the ChromaDex Corporation's Fourth Quarter 2024 earnings call, the company reported record revenues of $29.1 million, marking a 37% year-over-year increase, and net income of $7.2 million for the quarter. For the full year, ChromaDex achieved net revenues of $99.6 million, a 19% growth from the previous year, and net income of $8.6 million. The company generated a positive cash flow of $12.1 million from operations in 2024 and ended the year with $44.7 million in cash and no debt. The e-commerce channel experienced a 30% year-over-year growth with net sales of $17.3 million, while the Niagen ingredient business saw a 96% increase in sales year-over-year. Gross margins improved by 150 basis points to 62.5% in the fourth quarter. For 2025, ChromaDex projects an 18% growth in net sales, with anticipated modest improvements in gross margins. The company also plans to increase R&D and general administrative expenses while maintaining operational efficiency. Additionally, a corporate rebranding is expected to be announced in the coming weeks.Niagen Bioscience Corporate Events
Business Operations and StrategyFinancial Disclosures
Niagen Bioscience Reports Strong Q1 2025 Financial Results
Positive
May 7, 2025
On May 7, 2025, Niagen Bioscience, Inc. reported its financial results for the first quarter of 2025, revealing a significant year-over-year increase in net sales by 38% to $30.5 million, driven by strong demand for its Tru Niagen® and Niagen® ingredient products. The company achieved a gross margin of 63.4% and net income of $5.1 million, marking a substantial improvement from the previous year. Additionally, Niagen Bioscience announced an increased full-year outlook for 2025, expecting net sales growth between 20% and 25%, and highlighted its strategic rebranding and expansion of its NAD+ precursor patent portfolio, reinforcing its leadership in the healthy aging sector.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
Chromadex’s overall score reflects its strong financial performance with improved profitability and cash flow, despite revenue growth challenges. The stock shows positive technical momentum but is overvalued based on its P/E ratio. The promising outlook from the earnings call, despite some operational challenges, supports a favorable stock assessment.
To see Spark’s full report on NAGE stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.